Tough industry conditions and company-specific issues hit these stocks.
News & Analysis: Sorrento Therapeutics
Find out which bad news sent these stocks lower.
The biopharma stock is continuing to experience volatility today.
Good news from a preclinical study is exciting investors about the potential for one of Sorrento's experimental drugs.
The early-stage biotech jumped without any significant news.
A recently announced debt financing won't dilute shareholders, but it still has Wall Street worried.
From an analyst downgrade to new tariffs on China, see why these three companies fell on Thursday.
The biotech's share price dropped on no news -- but perhaps plenty of worries.
A recent fundraising effort has investors running for the exits.
A sell-the-news 24% drop. Oh my!